Biography

• Zonghai Li, M.D., Ph.D., is the leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute and a doctoral supervisor at Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine. He is the CEO and the Chief Scientific Officer at CARsgen Therapeutics. He obtained his Doctor degree from Fudan University in 2005. Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. Dr. Li has published more than 100 SCI papers in journals such as Nat Med, J Natl Cancer Inst, Cancer Immunol Res, Cancer Cell, Cancer Res, Clin Cancer Res, etc. In order to accelerate the transformation of scientific and technological achievements, he founded CARsgen Therapeutics company in 2014. He have developed novel technologies and a product pipeline with global rights to address major challenges of CAR-T cell therapies. The product pipeline includes an upgraded fully-human BCMA CAR-T(CT053), globally potential first-in-class Claudin18.2CAR-T(CT041) with the only IND clearance, and globally potential first-in-class GPC3CAR-T(CT011). There are eight IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China. Dr. Li was awarded the Leading Talents of Shanghai in 2018, the Shanghai Youth Science and Technology Award and the Shanghai May 1st.Labor Medal in 2019, New Century Excellent Talents in Ministry of Education in 2013, Shanghai Rising-Star in 2007.

Publications:

1. Changsong Qi, Jifang Gong, Jian Li,Dan Liu, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng,Jun Zhou, Yanshuo Cao, Xiaotian Zhang, Zhihao Lu, Ming Lu, Jiajia Yuan, Zhenghang Wang,Yakun Wang, Xiaohui Peng, Huiping Gao, Zhen Liu, Huamao Wang, Daijing Yuan, Jun Xiao,Hong Ma, Wei Wang, Zonghai Li and Lin Shen#. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022 Jun; 28(6):1189-1198

2. MinZhou, MuhuaChen, BizhiShi, ShengmengDi, RuixinSun, HuaJiang, Zonghai Li#. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-κB/Icam1 signaling. Mol Ther. 2022 Aug 4;S1525-0016(22)00442-7

3. Ruixin Sun, Hong Luo, Jingwen Su, Shengmeng Di, Min Zhou, Bizhi Shi, Yansha Sun, Guoxiu Du, Honghong Zhang, Hua Jiang#, Zonghai Li#. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2021 Jan 6;29(1): 60-74.

4. Hong Luo, Jingwen Su, Ruixin Sun, Yansha Sun, Yi Wang, Yiwei Dong, Bizhi Shi, Hua Jiang#, Zonghai Li#. Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion. Clin Cancer Res. 2020 Oct 15;26(20):5494-5505.

5. Donghua Shi, Yaoping Shi, Ahmed O Kaseb, Xingxing Qi, Yuan Zhang, Jiachang Chi, Qing Lu, Huiping Gao, Hua Jiang, Huamao Wang, Daijing Yuan, Hong Ma, Hongyang Wang, Zonghai Li# and Bo Zhai#. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin Cancer Res. 2020 Aug 1;26(15): 3979-3989.

6. Hua Jiang, Zhimin Shi, PengWang, Cong Wang, Linlin Yang, Guoxiu Du, Honghong Zhang, Bizhi Shi, Jie Jia, Qixiang Li, Huamao Wang, Zonghai Li#. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. J Natl Cancer Inst. 2019,111(4):409-418

7. Xiuqi Wu, Hong Luo, Bizhi Shi,Shengmeng Di,Ruixin Sun,Jingwen Su,Ying Liu, Hua Li,Hua Jiang,and Zonghai Li#. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Mol Ther. 2019 Aug 7;27(8):1483-1494.

8. Hua Jiang, Huiping Gao, Juan Kong, Bo Song, Peng Wang, Bizhi Shi, Huamao Wang, Zonghai Li#. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bi-targeted Chimeric Antigen Receptor T Cell. Cancer Immunol Res. 2018 ; 6(11):1314-1326

9. Min Yu, Hong Luo, Mingliang Fan,Xiuqi Wu, Bizhi Shi, Shengmeng Di, Ying Liu, Zeyan Pan, Hua Jiang,and Zonghai Li#. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Molecular Therapy. 2018, 26(2):366-378

10. Xiuqi Wu, Bizhi Shi, Jiqin Zhang, Zhimin Shi, Shengmeng Di, Minliang Fan, Huiping Gao, Hai Wang, Jianren Gu, Hua Jiang, Zonghai Li#. A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T cells. Molecular Therapy. 2017, 25(10):2270-2279

11. Huiping Gao, Kesang Li, Hong Tu, Xiaorong Pan, Hua Jiang, Bizhi Shi, Juan Kong,Hongyang Wang, Shengli Yang, Jianren Gu, and Zonghai Li#. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014,20(24):6418-28；

12. Min Zhou, Hai Wang, Keke Zhou, Xiaoying Luo, Xiaorong Pan, Bizhi Shi, Hua Jiang, Jiqin Zhang, Kesang Li, Hua-Mao Wang, Huiping Gao, Shun Lu, Ming Yao, Ying Mao, Hong-Yang Wang Shengli Yang, Jianren Gu, Chuanyuan Li, and Zonghai Li#. A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells. Cancer Res. 2013,73:7056-7067

13. Zonghai Li, Ruijiao Zhao, Xianghua Wu,Ye Sun, Ming Yao, Jinjun Li, Yuhong Xu, and Jianren Gu. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005, 19:1978–1985